ROS1 and cancer: Furthermore, the activation of bypass signalling as a method of crizotinib resistance in ROS1 cancer cells has been described in various studies and identified in approximately 45% of crizotinib-resistant ROS1-rearranged NSCLC malignancies (Figure 1) [80,81].